In the Specification:

Please amend the paragraph beginning at page 1, line 31 of the specification as follows:

--Co-pending PCT application No. ~~PCT/GB02/05743~~ PCT/GB02/05738 discloses compounds of formula ~~A~~ I



~~A~~ I

wherein n is 1 or 2 and pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof are highly potent PPARα modulators. PPAR is short peroxisome proliferator-activated receptors (for a review of the PPARs see T.M. Willson et al., J. Med. Chem. 2000, Vol. 43, 527). These compounds are effective in treating conditions associated with insulin resistance. Specific pharmaceutically acceptable salts of the compounds of the formula ~~A~~ I are not disclosed in ~~PCT/GB02/05743~~ PCT/GB02/05738. Further, no information is provided in relation to how crystalline forms of compounds of the formula ~~A~~ I, and particularly salts thereof, may be prepared. The compound in which n is 2 is prepared as the free acid in this application. However, this compound is a syrup and is not suitable for use in pharmaceutical formulations. Therefore there exists a need for a derivative of this compound which has physical and chemical properties suitable for use in pharmaceutical formulations. Attempts were made to produce salts with many different counter-ions. However, most were unsatisfactory for one of the following reasons. A salt could not be formed in the solid state of if formed the salt was amorphous with a low glass transition temperature.--

Please amend the paragraph beginning at page 4, line 5 of the specification as follows:

--Compounds of the invention, and particularly crystalline compounds of the invention, may have improved stability when compared to compounds disclosed in ~~PCT/GB02/05743~~ PCT/GB02/05738.--